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Novel Hypolipidemic Agents:  
Focus on PCSK9 Inhibitors
Antonis S. Manolis, MD,1 Theodora A. Manolis,2 MD, Helen Melita, MD3
A b s t r A c t
Proprotein convertase subtilisin/kexin type 9 (PCSK9) was recently discovered as the 
third gene involved in autosomal dominant familial hypercholesterolemia. The en-
coded PCSK9 protein binds and induces degradation of the low-density lipoprotein 
(LDL) receptor and thereby modulates the plasma levels of LDL-cholesterol. Some of 
the naturally occurring PCSK9 mutations increase the function of this protein (gain 
of function) and cause hypercholesterolemia, whereas loss of function mutations pro-
duce hypocholesterolemia. Since the loss of a functional PCSK9 in humans is not 
associated with apparent deleterious effects, this protease is an attractive target for 
the development of hypocholesterolemic agents, either alone or in combination with 
statins. Thus, inhibition of PCSK9 with monoclonal antibodies is emerging as a novel 
strategy for the treatment of hypercholesterolemia. Other novel hypolipidemic agents 
include mipomersen, an antisense oligonucleotide inhibitor targeted to human apoli-
poprotein B-100, and lomitapide, an oral microsomal triglyceride transfer protein 
inhibitor. Data obtained from preliminary studies show that these new therapeutic 
approaches are effective in reducing LDL-cholesterol. An overview of these novel 
hypolipidemic agents is herein attempted with a focus on PCSK9 inhibition.
I N t r O D U c t I O N
Familial hypercholesterolemia (FH) is the most common and severe form of mo-
nogenic hypercholesterolemia.1 FH was the first genetic disease of lipid metabolism 
to be clinically and molecularly characterized. A scientific breakthrough happened 
in the mid-1970s, when Brown and associates described the low-density lipoprotein 
(LDL)-receptor pathway;2 Goldstein and Brown demonstrated that defects in the 
LDL-receptor cause FH,3 a landmark discovery that earned the authors the Nobel 
Prize in Physiology or Medicine in 1985.4
The main biochemical abnormality in FH is elevated LDL-cholesterol in plasma, 
caused by reduced function of the LDL-receptor pathway, which removes LDL particles 
from the circulation into the liver.1 The majority (>90%) of cases of FH are caused 
by mutations in the gene of the LDL receptor; however, less commonly the etiology 
of FH may also include mutations in the gene of apolipoprotein B (apo B), and the 
proprotein convertase subtilisin/kexin type 9 gene (PCSK9). In addition to having an 
important structural role in LDL, apo B-100 also acts as a ligand for the LDL receptor 
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to facilitate clearance of LDL particles from plasma. Finally, 
rare heterozygous gain-of-function mutations in PCSK9 cause 
a severe form of FH by causing accelerated degradation of 
the LDL receptor. Patients with FH are characterized by 
a decreased clearance of LDL from the circulation and an 
increase in LDL synthesis; changes in homozygotes are more 
marked than in heterozygotes (a gene dosage effect).1 If un-
treated, patients develop premature atherosclerotic coronary 
artery disease. 
Hypercholesterolemia of whatever cause, typically due 
to a combination of environmental and genetic factors, is a 
major cardiovascular risk factor that accelerates the process 
of formation of atherosclerotic plaque,5 thus increasing the 
incidence of cardiovascular events (myocardial infarction and 
stroke). Reduction in plasma LDL-cholesterol is a mainstay of 
treatment for the prevention of these potentially catastrophic 
events. Currently, statins constitute the cornerstone of hy-
polipidemic drug therapy,6,7 as they reduce LDL-cholesterol 
levels by inhibiting the rate-limiting step in hepatic cholesterol 
synthesis; they block the conversion of 3-hydroxy- 3-methyl-
glutaryl coenzyme A (HMG-CoA) to mevalonate by inhibit-
ing the enzyme HMG-CoA reductase, resulting in increased 
expression of hepatic LDL receptors and increased clearance 
of circulating LDL-cholesterol.
Although statin therapy confers significant protection 
against acute coronary events in both primary and secondary 
prevention,6,7 a considerable residual risk remains after inten-
sive therapy. In addition, a significant proportion of high-risk 
patients do not achieve the optimal LDL-cholesterol goal 
recommended in the current guidelines.8 Hence, novel LDL-
cholesterol-lowering agents that act via mechanisms distinct 
from HMG-CoA reductase inhibition are under investigation.
Apolipoprotein b-100 (Apo B-100) is the major apolipopro-
tein and an essential component of all atherogenic lipoproteins, 
namely very low density lipoproteins (VLDL), LDL, interme-
diate-density lipoprotein (IDL), and lipoprotein(a) - Lp(a).9,10 
Apo B-100 drives many of the functions of lipoproteins, in-
cluding interaction with the LDL receptor. Plasma levels of 
apoB-100 are associated with a risk for cardiovascular disease. 
Incorporation of apoB-100 is necessary for the production 
and secretion of VLDL particles into the circulation. Hence, 
inhibition of apo B-100 synthesis would lead to decreased 
circulating levels of VLDL and all its remnant lipoproteins, 
including IDL, LDL, and Lp(a).
Microsomal triglyceride transfer protein (MttP) is 
an endoplasmic reticulum–associated protein with a central 
role in the biosynthesis and the secretion of apolipoprotein 
B-containing lipoproteins.9,11 Expressed in hepatocytes and 
enterocytes, MTTP mediates the transfer of neutral lipids 
(triglycerides and cholesterylesters) to the nascent apoB- 100 
and apoB-48 polypeptides, thereby promoting the assembly 
of VLDL and chylomicrons, respectively. Owing to its pivotal 
role in VLDL assembly and secretion, MTTP inhibition has 
been considered as an efficacious strategy for the treatment of 
dyslipidemia. Its pharmacological inhibition is associated with 
a decrease in LDL cholesterol and triglycerides. The concept 
of MTTP inhibition has been further validated by reports in 
patients with abetalipoproteinemia, a rare autosomal reces-
sive disorder characterized by defective and nonfunctional 
MTTP activity.9 These patients have very low levels of apoB-
containing lipoproteins in the circulation due to the absence 
of VLDL secretion and almost complete protection against 
atherosclerosis, albeit with significant hepatic accumulation 
of triglycerides, with ensuing steatosis and hepatomegaly, 
steatorrhea, elevated hepatic enzyme levels, and deficiencies 
of fat-soluble vitamins, untoward effects which are very similar 
to the side-effects of MTTP inhibitors. 
Proprotein convertase subtilisin/kexin type 9 (PcsK9) is 
a proteinase K–like enzyme of the secretory subtilase family.12 
This protein is primarily synthesized and secreted by hepato-
cytes. The best-known biological function of PCSK9 is regula-
tion of cholesterol homeostasis via accelerating the degradation 
of the LDL receptor by direct binding. PCSK9 decreases the 
LDL receptor density on the surface of hepatocytes either 
through inhibition of receptor recycling or through directing 
LDL receptors to lysosomal catabolism. Dominant gain-of-
function mutations in the PCSK9 gene cause a phenotype 
similar to familial hypercholesterolemia (FH),13 while loss-
of-function variants are associated with hypocholesterolemia 
and prevention of coronary artery disease.14 
Agents that inhibit PCSK9, apolipoprotein (apo) B, and 
MTTP are the most promising therapies. Inhibition of PCSK9, 
apoB, and MTTP has been achieved mostly via fully hu-
manized monoclonal antibodies, antisense oligonucleotides, 
and synthetic compounds, respectively. PCSK9 inhibitors 
increase the hepatic uptake of LDL-cholesterol, while apoB 
and MTTP inhibitors decrease the synthesis and secretion of 
apoB- containing lipoproteins. These 3 mechanisms lead to 
marked reductions in plasma LDL-cholesterol in patients with 
hypercholesterolemia at risk for acute coronary events, par-
ticularly those with familial hypercholesterolemia. Moreover, 
these agents can exert additional benefits by decreasing plasma 
levels of apoB, triglycerides, and lipoprotein(a). Mipomersen 
and lomitapide have recently been approved by the United 
States (US) Food and Drug Administration (FDA) for use 
in patients with homozygous familial hypercholesterolemia. 
PCSK9 inhibitors are currently under final evaluation in clinical 
outcomes studies and are anticipated to find wide application 
either as monotherapy or as an adjunct to statins. A main 
safety concern is the risk for hepatic steatosis with apoB and 
MTTP inhibitors, which needs to be explored in prospective, 
long-term trials.
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P r O P r O t E I N  c O N V E r t A s E  s U b t I l I s I N 
K E X I N  t y P E  9  ( P c s K 9 )
Proprotein convertase subtilisin kexin type 9 (PCSK9), 
as described above, is a protein (serine protease) synthesized 
and secreted mainly by the liver which binds to hepatic low-
density lipoprotein (LDL) receptors.15-17 It regulates plasma 
LDL-cholesterol levels by diverting cell surface LDL receptors 
to lysosomes for degradation. In so doing, PCSK9 prevents the 
normal recycling of LDL receptors back to the cell surface. This 
process results in reduced LDL receptor density, decreased 
clearance of LDL-cholesterol, and, consequently, accumulation 
of LDL-cholesterol in the circulation. Thus, PCSK9 levels tend 
to correlate directly with LDL-cholesterol levels.18 
Several mutations in the PCSK9 gene have been identi-
fied which are associated with either a hypocholesterolemic 
or hypercholesterolemic phenotype.13,15,19 “Loss-of-function” 
mutations in PCSK9 decrease LDL receptor degradation 
and patients with these mutations have life-long low levels of 
LDL-cholesterol and appear to be protected from coronary 
artery disease with significantly reduced cardiovascular risk. 
Conversely, “gain-of-function” mutations accelerate LDL 
receptor degradation and carriers of these mutations present 
with elevated LDL-cholesterol levels and increased cardiovas-
cular risk. In these patients, the clinical features are similar to 
those observed in FH patients with LDL receptor mutations. 
Statins do not only upregulate LDL receptors, but they also 
simultaneously upregulate expression and secretion of PCSK9 
via a process involving the sterol regulatory element-binding 
protein-2 (SREBP-2) transcription factor.19,20 Elevation in 
PCSK9 levels further diminishes the number of LDL receptors, 
thereby blunting the efficacy of statins. This may explain why 
most LDL-cholesterol reduction is achieved with the starting 
dose of a given statin and why doubling the statin dose only 
further reduces LDL-cholesterol concentrations modestly. It 
has been alleged that statins follow a rule of 6% in that whatever 
LDL-cholesterol reduction is achieved at a starting dose of a 
given statin is only improved upon an additional approximate 
6% with each doubling of the dose. Statin-induced increases in 
PCSK9 levels may, therefore, account for the less than expected 
incremental reduction of LDL-cholesterol concentrations in 
response to increasing doses of statins.19 Therefore, introduc-
ing a PCSK9 antagonist on top of a statin is predicted to be 
additive to statins and further lower LDL-cholesterol.
Thus, the search for a novel lipid-lowering therapy has 
recently focused on developing pharmacological approaches 
that block the capacity of PCSK9 to degrade LDL recep-
tors.21-28 Several monoclonal antibodies are being currently 
assessed in human clinical trials. These studies indicate that 
PCSK9 inhibition could be an alternative monotherapy for 
hypercholesterolemic patients who cannot tolerate statins. It 
might also be an effective therapy for patients who have not 
reached desirable LDL-cholesterol targets with use of statins. 
PCSK9 inhibitors used in combination with statins could reduce 
LDL-cholesterol levels further and may be of added benefit 
in the treatment of these high-risk patients.
P c s K 9  I N H I b I t I N G  A G E N t s  
A N D  s t U D I E s
The particular biology of the PCSK9 protein has hindered 
efforts to find a small molecule and produce an oral PCSK9 
inhibitor. However, the fact that this protein operates outside 
cells points to its vulnerability to attack by monoclonal antibod-
ies. Indeed, the most promising therapeutic strategy to inhibit 
PCSK9-mediated degradation of the LDL receptor appears 
to be the use of injectable monoclonal antibodies, a proven 
successful, albeit very expensive, form of biological medicine.15 
Several monoclonal antibodies to PCSK9, which mimic the 
effects of genetic mutations by inhibiting PCSK9, have been 
developed and are in clinical trials (Table 1). Amgen Inc (Thou-
sand Oaks, CA, USA) developed a humanized anti-PCSK9 
monoclonal antibody that blocked the PCSK9:LDL-receptor 
interaction. In Phase I studies, Amgen’s antibody (AMG145, 
now named Evolocumab) lowered LDL-cholesterol by up to 
64% in healthy subjects and by up to 81% in hypercholester-
olemic statin-treated subjects with or without heterozygous 
FH. Evolocumab also significantly reduced ApoB (~55%) 
and lipoprotein(a).17 Subsequently, evolocumab was tested 
in several 12-week Phase II studies. The Goal Achievement 
After Utilizing an Anti-PCSK9 Antibody in Statin-intolerant 
Subjects (GAUSS) trial assessed the efficacy and tolerability 
of the antibody as a monotherapy in statin-intolerant hyper-
cholesterolemic patients.21 The Reduction of LDL-C With 
PCSK9 Inhibition in Heterozygous Familial Hypercholester-
olemia Disorder (RUTHERFORD) trial tested evolocumab 
in patients with heterozygous FH with LDL-cholesterol ≥100 
mg/dL despite statin therapy with or without ezetimibe.22 The 
Monoclonal Antibody Against PCSK9 to Reduce Elevated 
LDL-C in Patients Currently Not Receiving Drug Therapy 
for Easing Lipid Levels (MENDEL) trial tested the antibody 
as a monotherapy in patients with hypercholesterolemia.23 
The LDL-C Assessment With PCSK9 Monoclonal Antibody 
Inhibition Combined With Statin Therapy-Thrombolysis 
in Myocardial Infarction 57 (LAPLACE-TIMI 57) trial as-
sessed the antibody in combination with a statin in patients 
with hypercholesterolemia.24 All four trials demonstrated 
that subcutaneous injections of evolocumab could reduce 
LDL-cholesterol by >50% either alone or in addition to 
other LDL-cholesterol-lowering therapies. Evolocumab was 
reported to be well tolerated, with no major adverse effects 
compared with placebo.
According with the results of phase II trial extension 
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studies (Open-Label Study of Long-term Evaluation Against 
LDL-C / OSLER), recently presented at the American Heart 
Association Meeting in Dallas and simultaneously published 
online in Circulation,25 evolocumab maintained drastically 
reduced cholesterol levels over 1 year. Mean reduction in 
LDL cholesterol was 52.1% over baseline at 1 year in the 
extension phase, similar to the 50.4% reduction seen in the 
initial 12-week phase II studies. Furthermore, patients in the 
control group in the initial studies who were switched onto the 
drug in the extension phase also demonstrated a mean 52.3% 
reduction in LDL over baseline by 1 year (P<0.0001). On the 
other hand, switching to statin therapy after initially being on 
evolocumab led to a return to baseline without rebound. There 
were no neutralizing anti-drug antibodies or other safety is-
sues emerging during the extension phase. The OSLER study 
included 1,104 patients from four separate phase II dose 
ranging studies that lasted 12 weeks (GAUSS, LAPLACE-
TIMI 57, RUTHERFORD, and MENDEL trials). All were 
randomized to either standard of care alone (including statin 
therapy) or open-label evolocumab subcutaneous injections 
at 420 mg every 4 weeks plus standard of care, regardless of 
their prior trial randomization. In the evolocumab group, LDL 
cholesterol levels dropped from a mean of 140 mg/dL to <100 
mg/dL at week 52 for 86% of patients and to <70 mg/dL for 
63%. For the standard-of-care arm, LDL cholesterol fell from 
a mean of 144 mg/dL at baseline to <100 mg/dL for 16% by 
52 weeks and to <70 mg/dL for just 1%. The PCSK9 inhibitor 
also reduced lipoprotein(a) by 30-33% in the extension phase, 
compared with a 9 - 11% reduction among patients on standard 
of care in the extension (P<0.0001). Evolocumab also reduced 
apolipoprotein A and B and triglycerides significantly more 
than the control therapy. Adverse events and serious adverse 
events occurred in 81.4% and 7.1% of the evolocumab-plus-
standard-of-care group patients and 73.1% and 6.3% of the 
standard-of-care-group patients, respectively. Musculoskeletal 
and connective tissue disorders were observed in 33.0% and 
34.7% of patients when LDL dropped below 50 or 25 mg/dL, 
respectively, compared with ~25% in those with levels of ≥50 
mg/dL. Injection site reactions occurred in ~5% of patients 
with evolocumab.
The effects of evolocumab on clinical outcomes will be 
assessed in the large phase 3 PROFICIO study program.15 A 
very important trial is the FOURIER (Further Cardiovascular 
Outcomes Research with PCSK9 Inhibition in Subjects With 
Elevated Risk) study testing the effects of evolocumab on car-
diovascular events in >20,000 patients with prior myocardial 
infarction or stroke, with at least 1 major or 2 minor coronary 
risk factors, and fasting LDL-cholesterol level ≥70 mg/dl or 
non-high-density lipoprotein cholesterol level of ≥100 mg/
dl receiving maximal tolerated doses of atorvastatin with or 
without ezetimibe (NCT01764633).9,26 
Alirocumab (formerly SAR236553/REGN727) is a highly 
specific, human monoclonal antibody to PCSK9 developed 
by Regeneron Pharmaceuticals, Inc (Tarrytown, Ny, USA) / 
Sanofi SA (Paris, France).27-29 In a study, reporting the results 
of three phase 1 trials, the administration of alirocumab signifi-
cantly reduced LDL cholesterol levels in healthy volunteers and 
in patients with familial or nonfamilial hypercholesterolemia; 
the effect was also significant in subjects who were concomi-
tantly taking atorvastatin (further reduction of LDL-cholesterol 
concentrations by up to 68%).27 A recent placebo-controlled 
study evaluated the LDL-cholesterol–lowering effect of 5 dosing 
regimens of alirocumab (50, 100, or 150 mg every 2 weeks; or 
200 or 300 mg every 4 weeks) vs placebo for a total treatment 
period of 12 weeks in 183 patients with LDL-cholesterol ≥100 
mg/dl maintained on stable atorvastatin therapy (10, 20, or 
40 mg for ≥6 weeks).28 This novel agent demonstrated a clear 
dose-response relationship with respect to percentage LDL-
cholesterol lowering for both every 2 and 4 weeks regimens: 
40%, 64%, and 72% with 50, 100, and 150 mg every 2 weeks, 
respectively, and 43% and 48% with 200 and 300 mg every 4 
weeks. LDL-cholesterol reduction with placebo at week 12 
was 5%. Alirocumab also substantially reduced non–HDL 
cholesterol, apolipoprotein B, and lipoprotein(a). The drug 
was generally well tolerated. One patient on the drug expe-
rienced a serious adverse event of leukocytoclastic vasculitis. 
The authors concluded that PCSK9 inhibition with alirocumab 
added to atorvastatin therapy further reduces LDL-cholesterol 
by 40-72%. These additional reductions were both dose- and 
dosing frequency–dependent. 
In another phase 2 study, 77 patients with heterozygous FH 
were randomly assigned to receive alirocumab 150 mg, 200 mg, 
or 300 mg every 4 weeks, or 150 mg every 2 weeks, or placebo 
every 2 weeks. LDL-cholesterol reduction from baseline to 
week 12 ranged from 29% for 150 mg every 4 weeks to 68% for 
150 mg every 2 weeks (p<0.0001), compared with 10.65% with 
placebo.29 No increases of >3 times the upper limit of normal 
were observed for hepatic transaminases or creatinine kinase. 
The most common adverse event was injection-site reaction 
with one patient in the group of 300 mg alirocumab terminating 
treatment. The authors concluded that the new drug was well 
tolerated and achieved substantial further LDL-cholesterol 
reduction in patients with heterozygous FH treated with high-
dose statins, with or without ezetimibe. Finally, the effects of 
alirocumab on clinical events are being assessed in the large 
phase 3 ODySSEy study program including the ODySSEy 
Outcome trial in 18,000 patients with a recent acute coronary 
syndrome (NCT01663402) (Table 1).9,15,17 
More programs using monoclonal antibodies inhibiting 
PCSK9 are in development, some of which are included in 
Table 1. To date, the two different commercial development 
programs presented above, which have produced the bulk of 
clinical data, have demonstrated significant success in lower-
ing LDL-cholesterol in phase 1 and 2 trials with similar agents 
(Evolocumab and Alirocumab). When administered subcutane-
ously at doses ranging from 50 to 150 mg every 2 weeks or 200 
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to 400 mg every 4 weeks, respectively, these agents produced 
similar dose-responses in LDL-cholesterol lowering. In hyper-
cholesterolemic patients, LDL-cholesterol reductions ranged 
up to 60%, and, as would be expected, an even greater response 
was reported for statin-treated hypercholesterolemic patients 
with up to 70% decrease. LDL-cholesterol has typically shown 
a gradual increase after the nadir as monoclonal antibodies 
are cleared from the circulation. Results to date indicate that 
the PCSK9 monoclonal antibody approach appears safe, 
well-tolerated, and significantly lowers LDL-cholesterol levels 
while also favorably affecting apolipoprotein B, triglycerides, 
lipoprotein (a), and HDL-cholesterol. This novel hypolipidemic 
therapy is expected to meet an important clinical need for 
patients unable to achieve adequate LDL-cholesterol-lowering 
with currently available therapies. 
O t H E r  N O V E l  H y P O l I P I D E M I c 
A G E N t s
Several other new agents are under investigation for their 
potentially beneficial treatment of homozygous familial hy-
percholesterolemia. Just recently, about 1 year ago, the first 
microsomal triglyceride transfer protein inhibitor, lomitapide, 
and the first antisense therapy to target apolipoprotein B, 
mipomersen, were granted FDA approval for the treatment 
of homozygous familial hypercholesterolemia, whereby LDL-
cholesterol levels are extremely elevated. 
Mipomersen (Kynamro™, Genzyme), administered as once-
weekly subcutaneous injection, is a second-generation antisense 
oligonucleotide inhibitor targeted to human apolipoprotein 
B (apoB)-100.10,30,31 Basically it is a nucleotide that is the mir-
ror image of the mRNA that encodes the apoprotein B-100 
protein and blocks its formation. Mipomersen is distributed 
mainly to the liver where it silences apoB mRNA, thereby 
reducing hepatic apoB-100 and leading to decreases in plasma 
total cholesterol, LDL-cholesterol, and apoB concentrations 
in a dose- and time-dependent manner. When given to FH 
patients on maximally tolerated doses of lipid-lowering therapy, 
LDL-cholesterol decreased by an additional 25%. The short-
term efficacy and safety of mipomersen appears to have been 
established, however, injection site reactions are common and 
concern exists regarding the long-term potential for hepatic 
steatosis. Thus, mipomersen given alone or in combination 
with standard lipid-lowering medications shows promise as 
an adjunct therapy in patients with homozygous or refractory 
heterozygous FH at high risk of coronary artery disease, who 
are not at target or are intolerant of statins. 
Lomitapide (Juxtapid™/Lojuxta™, Aegerion Pharma-
ceuticals), an oral inhibitor of the microsomal triglyceride 
transfer protein, inhibits the synthesis of chylomicrons and 
very low-density lipoprotein, thus reducing plasma levels of 
LDL-cholesterol by 40% in homozygous FH, as demonstrated 
in a multinational single-arm, open-label, 78-week, phase III 
trial, including 23 adults with homozygous FH.32 The initial 
dosage of lomitapide in the study was 5 mg once daily for two 
weeks, with upward titration up to 60 mg within 2-14 weeks 
as tolerated. Prior to commencing treatment with lomitapide, 
therapy with other lipid-lowering interventions (including LDL 
apheresis) was stabilized over a 6-week period, and continued 
throughout the lomitapide treatment phase. Lomitapide was 
generally well tolerated; the most common adverse events 
were gastrointestinal side-effects; importantly, transaminase 
elevation was noted in 34% of patients; it also caused hepatic 
steatosis with or without transaminase elevation.
These new hypolipidemic agents (lomitapide and mipom-
ersen) have the ability to significantly lower LDL-cholesterol, 
apo B, and non-HDL cholesterol levels, when administered 
concurrently with other lipid-lowering therapies. However, 
these agents carry a black box warning regarding the risk for 
transaminase elevations and hepatic steatosis, and are currently 
restricted by the FDA for use only in patients with homozy-
gous FH. Long-term safety and tolerability remain dubious. 
Inordinately high cost and potential risk for hepatotoxicity 
are currently the major limiting factors for their wider use.11 
The cholesteryl ester thransfer protein (CETP) transfers 
cholesteryl esters from high-density lipoprotein (HDL) to 
the apoB-containing lipoproteins. CETP deficiency leads to 
increased levels of HDL-cholesterol. Thus, inhibition of CETP 
was considered to be a target to increase HDL-cholesterol 
and potentially reduce atherosclerosis. Unfortunately, CETP 
inhibitors, like torcetrapid and dalcetrapid, either produced 
harm or failed to show any clinical benefit.10 Anacetrapib 
added to statin therapy has been demonstrated to reduce LDL-
cholesterol by a further ~40% and increase HDL-cholesterol by 
~140%.33 Whether it confers any clinical benefit by preventing 
cardiovascular events, is currently being investigated in the 
REVEAL trial.34
P E r s P E c t I V E
Most recently, new guidelines on cholesterol management 
were issued by the American Heart Association and the Ameri-
can College of Cardiology recommending strong measures 
for patients at particularly high risk of cardiovascular events, 
which include more aggressive therapy with the most potent 
statins, which are the only class of cholesterol-lowering drugs 
that the guidelines recommend for patients who can tolerate 
them.35 The guidelines dropped an emphasis on specific targets 
for lowering LDL levels. Instead, they suggest that individual 
patient risk assessment of developing heart disease rather than 
an LDL number should be used to determine the need for 
more intensive treatment. Thus, there is a concern that these 
guidelines that favor potent statins may threaten use or even 
approval of any new class of investigational cholesterol drugs 
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even if they are presented as more potent than conventional 
statin therapy. A potential drawback of the new agents is their 
injectable form compared to the convenience of oral formula-
tion of statins. Another major issue pertains to the results of 
future outcome studies with these novel agents. It is not just 
the degree of reduction in LDL-cholesterol that these agents 
confer, but the main point relates to whether this indeed 
impressive reduction translates into an improved patient 
outcome. The regulatory authorities may not approve the new 
agents on the basis of their ability to lower LDL cholesterol, 
but when and if the evidence of these ongoing “outcomes stud-
ies” eventually proves that the new agents actually lower the 
risk of cardiovascular events and the prediction is that these 
results will not be available before late 2017 or early 2018. Of 
course, there is always a safety issue with any new drug, and 
the results of just one-year follow-up is too short to draw any 
conclusions at all. Finally, cost issues will also prevail when 
these drugs become available, while the subcutaneous route 
of administration might be a problem and some may wish to 
wait for other oral alternatives,15,36 and many may put forth the 
issue of pleiotropic effects of statins which these newer agents 
do not seem to possess. 
c O N c l U s I O N
Proprotein convertase subtilisin/kexin type (PCSK9) protein 
plays an important role in the degradation of the LDL receptor 
and therefore in the LDL cholesterol catabolism. Preliminary 
clinical data of PCSK9 inhibition are quite promising and in-
dicate that the novel hypolipidemic agents targeting PCSK9, 
i.e. the PCSK9 inhibitors, may be a most effective treatment 
modality for dyslipidemia, particularly for those patients with 
refractory hypercholesterolemia, statin intolerance, or an 
elevated lipoprotein(a) level and associated cardiovascular dis-
eases. The most promising approach to inhibit PCSK9 activity 
appears to be the use of monoclonal antibodies, which produce 
a 50 - 70% LDL cholesterol reduction in addition to and to 
a greater extent than what has previously been attainable by 
maximal doses of statins. The most recent results of phase II 
clinical studies are promising and indicate a significant effect of 
LDL cholesterol reduction sustained over one year. However, 
apart from exuberant cost issues that need to be settled, safety 
and outcomes studies are needed with much longer clinical 
follow-up, before these agents are more widely adopted. 
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